Evidence map›Paper›PMID 40224162›Full record

ArticleHemaSphere2025

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study.

Martijn W C Verbeek, Michaela Reiterová, Anna Laqua, Beatriz Soriano Rodríguez, Lukasz Sedek, Chiara Buracchi, Malicorne Buysse, Elen Oliveira, Robby Engelmann, Joana Desterro and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Martijn W C VerbeekDepartment of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands.ORCID 0000-0002-7240-5176
Michaela ReiterováCLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic.
Anna LaquaDepartment of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany.
Beatriz Soriano RodríguezTranslational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.
Lukasz SedekDepartment of Microbiology and Immunology Medical University of Silesia Katowice Poland.
Chiara BuracchiPediatrics, Fondazione IRCCS San Gerardo dei Tintori Monza Italy.
Malicorne BuysseDepartment of Diagnostic Sciences Ghent University Ghent Belgium.
Elen OliveiraFaculty of Medicine Pediatrics Institute IPPMG Federal University of Rio de Janeiro Rio de Janeiro Brazil.
Robby EngelmannClinic III (Hematology, Oncology and Palliative Medicine), Special Hematology Laboratory, Rostock University Medical Center Rostock Germany.
Joana DesterroInstituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto Lisboa Portugal.
Anja X De JongPrincess Máxima Center for Pediatric Oncology Utrecht The Netherlands.
Sebastian BoettcherClinic III (Hematology, Oncology and Palliative Medicine), Special Hematology Laboratory, Rostock University Medical Center Rostock Germany.
Romana JugooaDepartment of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands.
Susana BarrenaTranslational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.
Saskia KohlscheenDepartment of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany.
Stefan NierkensPrincess Máxima Center for Pediatric Oncology Utrecht The Netherlands.
Joana G RodriquesInstituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto Lisboa Portugal.
Mattias HofmansDepartment of Diagnostic Sciences Ghent University Ghent Belgium.
Giuseppe GaipaPediatrics, Fondazione IRCCS San Gerardo dei Tintori Monza Italy.
Elaine Sobral de CostaFaculty of Medicine Pediatrics Institute IPPMG Federal University of Rio de Janeiro Rio de Janeiro Brazil.
Ester MejstrikovaCLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic.
Tomasz SzczepanskiDepartment of Pediatric Hematology and Oncology Medical University of Silesia Katowice Poland.
Monika BrüggemannDepartment of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany.
Jacques J M van DongenTranslational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.
Alberto OrfaoTranslational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain.
Vincent H J van der VeldenDepartment of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detection of minimal/measurable residual disease (MRD) is a critical prognostic marker in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The EuroFlow Consortium previously developed an 8-color flow cytometric MRD protocol, effective for >98% of BCP-ALL patients treated with chemotherapy. This study aimed to enhance MRD detection, particularly for patients treated with CD19-targeted therapies, by expanding the EuroFlow protocol to a 12-color panel. This new panel incorporates additional B-cell markers and exclusion T/NK-cell markers (CD3 and CD7). Through an evaluation of 237 diagnostic BCP-ALL samples, CD22, CD24, and HLA-DR were selected as additional B-cell gating markers. Two 12-color tubes were technically optimized and clinically validated across 101 patient follow-up samples, demonstrating excellent concordance with molecular MRD levels (

Identifiers

PMID40224162
PMCPMC11993931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.